EMA Authorised: Cosentyx (secukinumab) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Cosentyx (secukinumab) for psoriatic arthritis, psoriasis, and ankylosing spondylitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing. MAH: Novartis Europharm Limited. Decision date: 16/10/2025